Developing an open relationship with the drug industry

Lancet

Volumn 366, Issue 9491, 2005, Pages 1062-1064

  Vallance, Patrick ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; CYCLOOXYGENASE 2 INHIBITOR; FLUOXETINE; NONSTEROID ANTIINFLAMMATORY AGENT;

DECISION MAKING; DRUG EFFICACY; DRUG INDUSTRY; DRUG SAFETY; DRUG TOLERABILITY; GOVERNMENT; HEALTH CARE; HEALTH CARE COST; HEALTH SERVICE; HUMAN; MEDICAL LITERATURE; MEDICAL PRACTICE; MEDICAL RESEARCH; NOTE; PRIORITY JOURNAL; QUALITY OF LIFE; WELLBEING;

EID: 25144496582     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(05)66835-3     Document Type: Note

References (19)

1. NJ Wald, MR Law A strategy to reduce cardiovascular disease by more than 80% BMJ 326 2003 1419
2. Anon Cynical about the clinical Guardian 19 Jan 7, 2005
3. C Elliott Pharma goes to the laundry Hastings Centre Rep 34 2004 18 23
4. National Institute for Clinical Excellence Appraisal of beta interferon and glatiramer for the treatment of multiple sclerosis http://www.nice.org.uk/ page.aspx?o=27625 2000 (accessed April 18, 2005).
5. J Meikle Minister intervenes in row over drugs to treat Alzheimer's Guardian 8 March 14, 2005
6. American College of Rheumatology COX-2 agents have dramatically changed the NSAID landscape http://www.rheumatology.org/press/2004/fedutes_nsaid.asp 2004 (accessed April 18, 2005)
7. CK Kwoh New treatments are revolutionizing the management of rheumatoid arthritis http://www.rheumatology.org/public/usatoday/rheumatoid.asp 2004 (accessed April 18, 2005).
8. RD Altman, MC Hochberg, RW Moskowitz, TJ Schnitzer Recommendations for the medical management of osteoarthritis of the hip and knee www.rheumatology.org/publications/guidelines/oa-mgmt/oa-mgmt.asp September, 2005 (accessed April 18, 2005)
9. RS Bresalier, RS Sandler, H Quan Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial N Engl J Med 352 2005 1071 1080
10. CJ Hawkey COX-2 inhibitors Lancet 353 1999 307 313
11. L Tive Celecoxib clinical profile Rheumatology 39 suppl 2000 21 28
12. Anon Are refecoxib and celecoxib safer NSAIDS? Drug Ther Bull 38 2000 81 86
13. S Schneeweiss, RJ Glynn, J Avorn, DH Solomon A Medicare database review found that physician preferences increasingly outweighed patient characteristics as determinants of first time prescriptions for COX-2 inhibitors J Clin Epidemiol 58 2005 98 102
14. Anon Taking stock of coxibs Drug Ther Bull 43 2005 1 6
15. American Medical Association Module 4: American Medical Association ethical guidelines on gifts to physicians from industry http://www.ama-assn.org/ ama/pub/category/8691.html January 14, 2005 (accessed April 13, 2005)
16. B James Scrips' introduction to pharmaceutical marketing Scrip Rep Feb 24, 2004 http://www.pjbpubs.com/cms.asp?pageid=1574 (accessed April 18, 2005)
17. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group Randomized trial of intravenous streptokinase, oral aspirin, both, or either among 17 187 cases of suspected myocardial infarction: ISIS-2 Lancet 2 1988 349 360
18. I Goldtsein, TF Lue, H Pasma-Nathan, RC Rosen, WD Steers, PA Wicker Oral sildenafil in the treatment of erectile dysfunction N Engl J Med 338 1998 1397 1404
19. International Committee of Medical Journal Editors Uniform requirements for manuscripts submitted to biomedical journals: writing and editing for biomedical publication http://www.icmje.org/index.html#author October, 2004 (accessed 19 April 2005)